Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that its CEO, Douglas Love, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 p.m. ET. The presentation will focus on their innovative complement medicines targeting autoimmune and neurodegenerative disorders. A live webcast will be available on their website, with a replay accessible for 30 days post-event.

Annexon's pipeline includes product candidates like ANX005, ANX007, and ANX009, designed to disrupt the C1q pathway.

News Market Reaction – ANNX

-7.79%

-7.79% Session move

In the trading session that priced this news, ANNX declined 7.79%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:45 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. The company’s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

FAQ

What will Annexon present at the J.P. Morgan Healthcare Conference 2022?

Annexon will present its innovative complement medicines targeting autoimmune and neurodegenerative disorders.

When is Douglas Love's presentation at the J.P. Morgan Healthcare Conference?

Douglas Love's presentation is scheduled for January 11, 2022, at 3:45 p.m. ET.

How can I access the presentation from Annexon at the conference?

You can access the live webcast on Annexon's Investors page, with a replay available for 30 days after.

What products is Annexon developing related to complement medicines?

Annexon is developing ANX005, ANX007, and ANX009, which target the C1q pathway.

What is the focus of Annexon's clinical-stage pipeline?

Annexon's pipeline focuses on complement-mediated autoimmune and neurodegenerative disorders.